[go: up one dir, main page]

DE69735502D1 - LAG-3 PROTEIN MUTANTS, THEIR EXPRESSION AND USE - Google Patents

LAG-3 PROTEIN MUTANTS, THEIR EXPRESSION AND USE

Info

Publication number
DE69735502D1
DE69735502D1 DE69735502T DE69735502T DE69735502D1 DE 69735502 D1 DE69735502 D1 DE 69735502D1 DE 69735502 T DE69735502 T DE 69735502T DE 69735502 T DE69735502 T DE 69735502T DE 69735502 D1 DE69735502 D1 DE 69735502D1
Authority
DE
Germany
Prior art keywords
lag
expression
protein mutants
protein
mutants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69735502T
Other languages
German (de)
Other versions
DE69735502T2 (en
Inventor
Tayar Nabil El
Renato Mastrangeli
Bertrand Huard
Frederic Triebel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Applied Research Systems ARS Holding NV
Original Assignee
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Gustave Roussy (IGR), Institut National de la Sante et de la Recherche Medicale INSERM, Applied Research Systems ARS Holding NV filed Critical Institut Gustave Roussy (IGR)
Application granted granted Critical
Publication of DE69735502D1 publication Critical patent/DE69735502D1/en
Publication of DE69735502T2 publication Critical patent/DE69735502T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention concerns a purified polypeptide corresponding to a mutated form of the soluble LAG-3 protein or of one of its fragments comprising the extra-cellular domain D1 and D2.
DE69735502T 1996-11-28 1997-11-25 LAG-3 PROTEIN MUTANTS, THEIR EXPRESSION AND USE Expired - Lifetime DE69735502T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9614608 1996-11-28
FR9614608 1996-11-28
PCT/FR1997/002126 WO1998023741A1 (en) 1996-11-28 1997-11-25 Mutants of the lag-3 proteins, products for the expression of these mutants and use

Publications (2)

Publication Number Publication Date
DE69735502D1 true DE69735502D1 (en) 2006-05-11
DE69735502T2 DE69735502T2 (en) 2006-12-14

Family

ID=9498133

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69735502T Expired - Lifetime DE69735502T2 (en) 1996-11-28 1997-11-25 LAG-3 PROTEIN MUTANTS, THEIR EXPRESSION AND USE

Country Status (9)

Country Link
US (1) US6482925B1 (en)
EP (1) EP0942973B1 (en)
JP (1) JP2000516101A (en)
AT (1) ATE320488T1 (en)
AU (1) AU728911B2 (en)
CA (1) CA2273080C (en)
DE (1) DE69735502T2 (en)
IL (1) IL130123A (en)
WO (1) WO1998023741A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2659893A3 (en) * 2003-02-28 2014-02-12 The Johns Hopkins University T cell regulation
FR2868781B1 (en) 2004-04-13 2008-02-22 Immutep VACCINE COMPOSITION COMPRISING ANTIGEN-COUPLED CLAY II MHC LIGAND, METHOD OF PREPARATION AND USES
FR2902101B1 (en) 2006-06-12 2012-12-28 Scras PEPTIDES WITH ANTI-PROLIFERATIVE ACTIVITY
KR100808925B1 (en) 2006-09-29 2008-03-03 고려대학교 산학협력단 Pig LAB-3 Fusion Immunoglobulins
EP2044949A1 (en) * 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
EP3357511B1 (en) 2011-06-30 2020-05-13 Genzyme Corporation Inhibitors of t-cell activation
UY34887A (en) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
PT3508502T (en) 2013-09-20 2023-06-22 Bristol Myers Squibb Co Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
LT3116909T (en) 2014-03-14 2020-02-10 Novartis Ag ANTI-BODY MOLECULES AGAINST LAG-3 AND THEIR USE
TWI693232B (en) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
JO3663B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
TWI773646B (en) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
AU2016291817A1 (en) 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
SG10201906059VA (en) 2015-07-30 2019-08-27 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
CR20180318A (en) 2015-12-14 2018-09-19 Macrogenics Inc BISPECIFIC MOLECULES THAT HAVE IMMUNORREACTIVITY WITH PD-1 AND CTLA-4, AND METHODS OF USE OF THE SAME
BR112018012352A2 (en) 2015-12-16 2018-12-11 Merck Sharp & Dohme Corp. anti-lag3 antibodies and antigen binding fragments
IL322104A (en) 2017-05-30 2025-09-01 Bristol Myers Squibb Co Treatment of tumors that express LAG–3
AU2018275209A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9507618A (en) * 1994-05-06 1997-08-19 Roussy Inst Gustave Soluble polypeptide fractions of the lag-3 protein production process therapeutic composition anti-idiotype antibodies

Also Published As

Publication number Publication date
IL130123A (en) 2007-07-24
AU5229498A (en) 1998-06-22
DE69735502T2 (en) 2006-12-14
CA2273080A1 (en) 1998-06-04
IL130123A0 (en) 2000-06-01
WO1998023741A1 (en) 1998-06-04
EP0942973A1 (en) 1999-09-22
US6482925B1 (en) 2002-11-19
AU728911B2 (en) 2001-01-18
EP0942973B1 (en) 2006-03-15
JP2000516101A (en) 2000-12-05
ATE320488T1 (en) 2006-04-15
CA2273080C (en) 2004-11-09

Similar Documents

Publication Publication Date Title
DE69735502D1 (en) LAG-3 PROTEIN MUTANTS, THEIR EXPRESSION AND USE
DK0960127T3 (en) Isolated dimeric fibroblast activating protein alpha and uses thereof
BG102071A (en) Minor molecule inhibitors of rotamase enzymic activity
DE69535147D1 (en) OVEREXPRESSION OF MAMMAL AND VIRUS PROTEINS
DE68916512D1 (en) Composition for reducing post-operative adhesions and their use.
ATE476495T1 (en) BACILLUS THURINGIENSIS AND ITS INSECTICIDAL PROTEINS
DE69732881D1 (en) USE OF COMPOSITIONS WITH STABILIZED ENZYMES
DE50012863D1 (en) STRUCTURAL PROTEIN OF ADENO-ASSOCIATED VIRUS WITH CHANGED CHROMATOGRAPHIC PROPERTIES
NO971875D0 (en) Cathepsin 02 protease
DE69531958D1 (en) (1-3) -BETA-D-GLUUCON-BINDING PROTEIN, ANTIBODY DETECTING THIS PROTEIN AND USE OF THE PROTEIN AND ANTIBODY
ATE262537T1 (en) ENDOTHELAR CELL PROLIFERATION INHIBITOR AND USE THEREOF
EP0875567A3 (en) Mycbinding Zinc-finger proteins, preparation and use thereof
DK0901526T3 (en) Cortistatin: neuropeptides, compositions and methods
DE69111768D1 (en) Enzymatic composition for the determination of ethanol.
DK1012186T3 (en) Keratinocyte Growth Factors and Uses thereof
WO2000017328A3 (en) Fibrils
EA200000875A1 (en) PROTEINS INTERACTING WITH CASPASE-8
DE3786616D1 (en) BACILLUS BREVIS STEM AND THEIR USE.
DK0942992T3 (en) O-fucosyltransferase
DE69535337D1 (en) TRANSCRIPTION FACTOR E2F-5
DE60042273D1 (en) ANTITUMAN ANTIBODIES, PROTEINS AND ITS USE
ATE258053T1 (en) USE OF FLUPIRTINE FOR THE THERAPY AND PROPHYLAXIS OF MYOCARDIAL INFARCTION, SHOCK KIDNEY AND SHOCK LUNG
DE69409961D1 (en) TRIARYLETHYLENE DERIVATIVES FOR THERAPEUTIC USE
DE69733026D1 (en) CYCLIN E SPECIFIC DESIGNS AND COMPLEXES
BG102937A (en) Zona pelucida proteins as contraceptives

Legal Events

Date Code Title Description
8364 No opposition during term of opposition